OPRX · OptimizeRx Corp · Financials
5 customers — 47% of revenue (the year ended December 31, 2025)
“Our top five customers represented approximately 47% and 49% of our revenue for the years ended December 31, 2025 and 2024, respectively.”
One customer — 10% of revenue (fiscal 2025)
“one customer that accounted for approximately 10% of total revenue in fiscal 2025 did not generate revenue during the current period, and future revenue from this customer is uncertain.”
3 customers — 10% of revenue (2025)
“In 2025 and 2024, we had three customers and two customers, respectively, that represented more than 10% of our revenues.”
5 customers — 49% of revenue (the year ended December 31, 2024)
“Our top five customers represented approximately 47% and 49% of our revenue for the years ended December 31, 2025 and 2024, respectively.”
2 customers — 10% of revenue (2024)
“In 2025 and 2024, we had three customers and two customers, respectively, that represented more than 10% of our revenues.”
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $95M – $100M | $98.65M | $109.43MG | $92.13MG | $71.52MG | $62.45MG | $61.29M | $43.31M | $24.6M | $21.21M | $12.13M | $7.75M | $7.22M | $6.5M | $4.68M | $1.99M | $1.11M | $71.07K | |
| — | $26.42M | $35.83M | $32.75M | $28.62M | $23.48M | $25.65M | $19.21M | $9.16M | $9M | — | — | — | — | — | — | — | — | |
| — | $72.24M | $73.6M | $59.38M | $42.9M | $38.97M | $35.64M | $24.11M | $15.44M | $12.21M | $5.95M | $4.34M | $3.6M | $3.28M | $2.82M | $1.87M | — | — | |
| — | — | 67.25% | 64.45% | 59.98% | 62.4% | 58.14% | 55.65% | 62.77% | 57.56% | 49.09% | 55.99% | 49.84% | 50.46% | 60.23% | 94.2% | — | — | |
| — | — | $0 | $0 | — | — | — | $0 | $1.6M | $0 | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | $288.3K | $269.45K | $445.91K | — | |
| — | — | — | — | — | $33.49M | $27.7M | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | $4.23M | $4.22M | $2.3M | — | — | — | — | — | — | — | — | — | $57.87K | $54.71K | — | — | |
| — | $4.29M | $4.33M | $4.33M | $2.4M | $2.02M | $1.97M | $2.08M | $1.28M | $316.5K | $324.55K | $235.28K | $333.95K | $264.34K | $193.79K | $187.1K | $145.32K | $59.93K | |
| — | — | $61.9M | $73.08M | $69.3M | $51.26M | $35.28M | $26.24M | $19.13M | $12.03M | $8.08M | $5.92M | $4.2M | $4.31M | $3.09M | $2.33M | $2.57M | $1.92M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $2.41M | $2.57M | — | |
| — | $10.9M | $11.69M | -$13.71M | -$26.4M | -$12.29M | $361.1K | -$2.14M | -$3.69M | $180.13K | -$2.13M | -$1.58M | -$597.41K | -$1.03M | -$267.54K | -$454.92K | -$1.45M | -$1.85M | |
| — | — | 10.69% | -14.88% | -36.91% | -19.68% | 0.59% | -4.93% | -15.02% | 0.85% | -17.56% | -20.4% | -8.27% | -15.78% | -5.72% | -22.87% | -130.81% | -2597.95% | |
| — | $15.18M | $16.02M | -$9.38M | -$24M | -$10.27M | $2.33M | -$59.43K | -$2.41M | $496.63K | -$1.81M | -$1.35M | -$263.46K | -$761.99K | -$73.75K | -$267.82K | -$1.31M | -$1.79M | |
| — | $4.68M | $5.29M | $6.16M | $1.45M | — | — | — | — | — | — | — | $0 | $0 | $0 | $100 | $958.64K | -$106.55K | |
| — | $333K | $353K | $329K | $2.19M | $852.3K | $16.98K | $68.58K | $288.03K | $46.21K | $25.94K | $42.31K | — | — | — | — | $1290 | $2842 | |
| — | -$4.15M | -$4.74M | -$5.68M | $1.24M | $852.3K | $16.98K | -$71.81K | -$346.97K | $46.21K | $25.94K | $42.31K | $2267 | $935 | $246 | — | — | — | |
| — | $6.75M | $6.95M | -$19.39M | -$25.16M | -$11.44M | $378.08K | -$2.21M | -$4.04M | $226.34K | -$2.1M | -$1.54M | -$595.14K | -$1.03M | -$267.29K | — | — | — | |
| — | $2.15M | $1.82M | $725K | -$7.6M | — | — | — | -$897.96K | — | — | — | $0 | $0 | $0 | — | — | — | |
| — | $4.6M | $5.13M | -$20.11M | -$17.57M | -$11.44M | $378.08K | -$2.21M | -$3.14M | $226.34K | -$2.1M | -$1.54M | -$595.14K | -$1.03M | -$267.29K | -$454.55K | -$2.12M | -$2.01M | |
| — | — | 4.69% | -21.83% | -24.56% | -18.32% | 0.62% | -5.1% | -12.78% | 1.07% | -17.35% | -19.86% | -8.24% | -15.77% | -5.71% | -22.85% | -190.8% | -2827.02% | |
| — | — | $5.13M | -$20.11M | -$17.57M | -$11.44M | $378.08K | -$2.21M | -$3.14M | $226.34K | — | — | — | — | — | — | — | — | |
| USD/shares | — | $0.25 | $0.28 | -$1.10 | -$1.03 | -$0.64 | $0.02 | -$0.15 | -$0.23 | $0.02 | -$0.21 | -$0.05 | -$0.02 | -$0.04 | — | — | — | — |
| USD/shares | — | $0.24 | $0.27 | -$1.10 | -$1.03 | -$0.64 | $0.02 | -$0.15 | -$0.23 | $0.02 | -$0.21 | — | — | — | — | — | — | — |
| shares | — | — | 18.56M | 18.29M | 17.12M | 17.78M | 17.23M | 14.83M | 13.39M | 10.83M | 9.82M | 29.71M | 24.56M | 22.38M | 14.39M | 17.21M | — | — |
| shares | — | — | 19M | 18.29M | 17.12M | 17.78M | 17.69M | 14.83M | 13.39M | 11.86M | 9.82M | 29.71M | — | 24.01M | 21.2M | 17.21M | — | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2016–FY2023: $28.74M in buybacks.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Long-term debt, including current maturities | 2026-06-30 | USD 19,688,000 | 10-Q filed 2026-08-13 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Operating lease liabilities | 2026-06-30 | USD 473,000 | 10-Q filed 2026-08-13 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 25 similar-size Health Information Services companies (of 50 listed).
EV/Adj. EBITDA uses the company-stated “Adjusted EBITDA”, extracted from the reconciliation in its SEC filings — the company's own non-GAAP definition, not an XBRL-tagged figure.
Valuation over time computed as of each quarter's filing date
EV/Adj. EBITDA uses the company-stated “Adjusted EBITDA”, extracted from the reconciliation in its SEC filings as it existed at each sample date — the company's own non-GAAP definition, not an XBRL-tagged figure. Each point's tooltip names its TTM or fiscal-year basis.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| Life Science Companies | $109,214,000 | $85,469,000 |
| Other Revenue | $215,000 | $6,658,000 |